Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ROBERT MARSH

Allopathic & Osteopathic Physicians Family Medicine

NPI
1659428019
CMS profile
780444
Location
MINNETONKA, MN

General Payments · PY2018–2024

$268,855.43

  • Reported across 168 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$50,927.64

28 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $50,825.00 27
Travel and Lodging $102.64 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $50,927.64 28

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $17,600.00 10
PY2019 $34,873.04 24
PY2020 $45,950.19 31
PY2021 $43,136.40 27
PY2022 $44,263.80 28
PY2023 $32,104.36 20
PY2024 $50,927.64 28

Payment records · PY2024 (28)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137630010 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137630012 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137630014 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137630016 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137630018 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137630020 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137630022 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137630024 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137630026 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137630028 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137630030 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137630032 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 07/03/2024 Consulting Fee Undisputed 01/23/2026 1137630034 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137630036 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137630038 CMS
Takeda Pharmaceuticals U.S.A., Inc. $950.00 07/15/2024 Consulting Fee Undisputed 01/23/2026 1137630040 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137630042 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137630044 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,375.00 08/14/2024 Consulting Fee Undisputed 01/23/2026 1137630046 CMS
Takeda Pharmaceuticals U.S.A., Inc. $102.64 08/14/2024 Travel and Lodging Undisputed 01/23/2026 1137630048 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137630050 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137630052 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137630054 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137630056 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137630058 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137630060 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137630062 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,900.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137630064 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.